Effects on striatal and mesolimbic dopamine systems of a new potential antipsychotic drug -mezilamine- with weak cataleptogenic properties.
D000067956:Adenylyl Cyclase Inhibitors; D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D002395:Catecholamines / Q000378:metabolism; D003342:Corpus Striatum / Q000201:enzymology / Q000378:metabolism*; D004298:Dopamine / Q000378:metabolism*; D006719:Homovanillic Acid / Q000378:metabolism; D066298:In Vitro Techniques; D008032:Limbic System / Q000201:enzymology / Q000378:metabolism*; D008297:Male; D010879:Piperazines / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology*; D051381:Rats; D013997:Time Factors
D000067956:Adenylyl Cyclase Inhibitors; D014150:Antipsychotic Agents; D002395:Catecholamines; D010879:Piperazines; D011743:Pyrimidines; C014287:mezilamine; D004298:Dopamine; D006719:Homovanillic Acid